Last reviewed · How we verify
Placebo of AFATINIB
Placebo of AFATINIB is a Small molecule drug developed by Centre Leon Berard. It is currently in Phase 3 development. Also known as: Placebo of BIBW 2992.
This is a placebo control arm and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of AFATINIB |
|---|---|
| Also known as | Placebo of BIBW 2992 |
| Sponsor | Centre Leon Berard |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations are inert substances used as control comparators in clinical trials to establish the efficacy of the active drug through blinded comparison. In this Phase 3 trial, the placebo arm allows researchers to distinguish genuine therapeutic effects of afatinib from natural disease progression or patient expectation effects.
Approved indications
Common side effects
Key clinical trials
- Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence (PHASE2)
- Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (PHASE3)
- Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect (PHASE3)
- Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck (PHASE3)
- LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy (PHASE3)
- LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy (PHASE3)
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of AFATINIB CI brief — competitive landscape report
- Placebo of AFATINIB updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI
Frequently asked questions about Placebo of AFATINIB
What is Placebo of AFATINIB?
How does Placebo of AFATINIB work?
Who makes Placebo of AFATINIB?
Is Placebo of AFATINIB also known as anything else?
What development phase is Placebo of AFATINIB in?
Related
- Manufacturer: Centre Leon Berard — full pipeline
- Also known as: Placebo of BIBW 2992
- Compare: Placebo of AFATINIB vs similar drugs
- Pricing: Placebo of AFATINIB cost, discount & access